JP Patent

JP5963005B2 — 膵臓癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー

Assigned to エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト · Expires 2016-08-03 · 10y expired

What this patent protects

Patent listed against lenvatinib-mesylate.

Drugs covered by this patent

Patent Metadata

Patent number
JP5963005B2
Jurisdiction
JP
Classification
—
Expires
2016-08-03
Drug substance claim
No
Drug product claim
No
Assignee
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.